josh hardman
@josh-hardman.bsky.social
full of microplastics and writing about psychedelics at psychedelicalpha.com ( @psychedelicalpha.bsky.social )
What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care psychedelicalpha.com/news/what-ap...
What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care
Cleveland Clinic staff psychiatrist and psychedelic trialist Brian Barnett sits down with Psychedelic Alpha’s Josh Hardman to discuss psychiatrists’ perceptions of the field, the role of ketamine in ‘...
psychedelicalpha.com
Psychedelic Alpha turns 6 this month. To mark the occasion, we have completely rebuilt the website: new design, faster performance, better navigation across Bulletins, data products, interviews, and more. Explore the new site: psychedelicalpha.com
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression. psychedelicalpha.com/news/after-t...
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data - Psychedelic Alpha
Researchers, clinicians and executives react to Compass Pathways’ second positive Phase 3 psilocybin readout in treatment-resistant depression.
psychedelicalpha.com
Someone has written a 'Request for Congressional Oversight' of certain psychedelics orgs Psymposia and Psychedelic Alpha = only sources cited. PSA: Psychedelic Alpha is not involved. In fact, the author harassed me last spring and threatened to contact Interpol(!) Bizarre.
⚖️🇺🇲 January 2026 Psychedelic Bill Round-Up: 75 Bills in Flight... and Counting Legislative sessions across the U.S. have got off to a lively start this year, with dozens of new psychedelics-related bills introduced. psychedelicalpha.com/news/january...
Introducing the Pα+ Psychedelic Bill Tracker Monitor the status of every psychedelics-related bill working its way through both state and federal legislatures in the U.S. Available now: psychedelicalpha.com/data/psyched...
Psychedelic Bill Tracker - Psychedelic Alpha
A Pα+ tool that allows you to monitor the status of psychedelics-related bills working their way through both state and federal legislatures in the U.S.
psychedelicalpha.com
New: Ipsos/Psychedelic Alpha polling on how Americans view psychedelics. "With psychedelic mental health therapies on the horizon, Americans are open to learning more" www.ipsos.com/en-us/psyche...
With psychedelic mental health therapies on the horizon, Americans are open to learning more
Ipsos research examines information pathways and attitudes regarding the use of psychedelics in mental health treatment
ipsos.com
Pα+ Psychedelic Bulletin #217: - Gilgamesh’s GM-1020 Prints Positive Topline - FDA Lifts Hold on GH Research’s 5-MeO-DMT IND - Compass Details Pivotal PTSD Trial Design - Cybin Becomes Helus - much more... psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus - Psychedelic ...
Gilgamesh Prints Positive Topline from Phase 2a Study of NMDA Receptor Agonist for MDD • FDA Lifts Hold on GH Research’s Inhaled 5-MeO-DMT IND After More than Two Years • Cybin Rebrands to Helus…
psychedelicalpha.com
🎥 2025 Year in Review: Future(s) & Open Questions Watch the third and final video in our 2025 Year in Review series. psychedelicalpha.com/news/2025-ye...
2025 Year in Review: Future(s) & Open Questions (Video) - Psychedelic Alpha
In the third video of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look at some broader open questions and potential futures in the psychedelics field via a narrated presentation.
psychedelicalpha.com
🎥 Out now: Part 1 of our 3-part 2025 Year in Review video Series In this session, I take stock of where the psychedelics field stands today across drug development, policy, and access programmes in this hour-long video, which focuses on 2025. psychedelicalpha.com/news/year-in...
Year in Review: Psychedelics in 2025 (Video) - Psychedelic Alpha
In the first of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look back at 2025 via a narrated presentation. In this hour-long video, Hardman reviews developments across psychedelic…
psychedelicalpha.com
Pα+ Psychedelic Bulletin #216: - Australia’s Psychedelics-for-Veterans Funding - New Mexico Targets 2026 Medical Psilocybin Launch - Otsuka’s “Novel Serotonergic Agonists” - Psilocybin Accelerates Brain Tumour Growth in Mice - TX $50M Ibogaine Study psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026 Medical Psilocybin Launch; Radial Scores $50M; Otsuka’s “Novel Serotonergic Agonists”; Psilocybin ...
Australia’s Department of Veterans’ Affairs Explains World-First Funding Model for Psychedelic-Assisted Psychotherapy • New Mexico Targets December 2026 for Medical Psilocybin Launch •
psychedelicalpha.com
🐁 Very concerning finding: Psilocybin promotes brain tumour growth Authors caution against use of 5-HT2A agonists like psilocybin in patients with glioma, "given the profound and sustained tumor growth-promoting effects observed." Extends to other serotonergic drugs like LSD.
The Psychedelic Practitioner Issue 2: Preparation We explore the science and practice of psychedelic preparation through interviews, research reviews, and practitioner insights. Read now: psychedelicalpha.com/news/the-psy...
The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon I report from Washington, D.C., where conversations with regulators, lawmakers, and insiders suggest a turbulent but potentially transformative period ahead. psychedelicalpha.com/news/the-vie...
The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon - Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman reports from Washington, D.C., where conversations with regulators, lawmakers, and insiders suggest a turbulent but potentially transformative period ahead.
psychedelicalpha.com
Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition I spoke with the Compass exec at a pivotal time for the company, covering clinical infrastructure and credentialing through to comps and competition. psychedelicalpha.com/news/bringin...
Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition - Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman sits down with Compass Pathways’ Chief Patient Officer, Steve Levine, at a pivotal time for the company. In this wide-ranging discussion, the pair cover these…
psychedelicalpha.com
BREAKING: ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics The U.S government agency revealed the project this evening. Read our breaking news story... psychedelicalpha.com/news/arpa-h-...
ARPA-H Launches $100M Effort to “Demystify” Mental Health and Catalyse Rapid-Acting Behavioural Health Therapeutics, Including Psychedelics - Psychedelic Alpha
The Advanced Research Projects Agency for Health (ARPA-H) has carved out up to $100M for an initiative that aims to develop objective measures of mental and behavioural health, it announced today.
psychedelicalpha.com
Psychedelic Bulletin 214: - Largest LSD Microdosing Trial Fails Across All Endpoints - AtaiBeckley’s Phase 2b Debrief - UK Gov. Holds Line on Psilocybin Despite MPs' Written Questions - MAHA Summit ft. Psychedelics - VA's Ph 3 Psilocybin Study - More... psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions - Psychedelic Alpha
Largest LSD Microdosing Trial to Date Fails Across All Endpoints • AtaiBeckley’s Phase 2b Debrief: More Detail on SAE and Phase 3 Considerations • UK Government Holds Line on Psilocybin Despite New…
psychedelicalpha.com
Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action psychedelicalpha.com/news/beyond-...
Beyond the Brain Reset: Óscar Soto on Mechanisms of Psychedelic Action - Psychedelic Alpha
In this interview with Psychedelic Alpha’s Josh Hardman, psychiatrist, therapist and researcher Dr. Óscar Soto discusses psychedelic trial design, therapeutic fidelity, and the evolving role of…
psychedelicalpha.com
AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3 We reviewed the readout and spoke with AtaiBeckley ( $ATAI ) CEO, Srinivas Rao, to dive deeper… psychedelicalpha.com/news/ataibec...
AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3 - Psychedelic Alpha
This morning, AtaiBeckley shared positive topline data from the open-label portion of its Phase 2b trial of intranasal 5-MeO-DMT (BPL-003) in patients with treatment-resistant depression (TRD)…
psychedelicalpha.com
Psychedelic Bulletin 213 - Compass Accelerates Psilocybin Launch Plans by Almost a Year - Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans - AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidate psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate - Psychedelic A...
Compass Accelerates Psilocybin Launch Plans by Almost a Year • Australia’s VA Will Fund Psychedelic-Assisted Psychotherapy for Veterans • AbbVie Paid $900M Upfront for Gilgamesh’s Psychedelic Candidat...
psychedelicalpha.com
BREAKING: Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months More detail, including interview with $CMPS CEO Kabir Nath, in our coverage... psychedelicalpha.com/news/compass...
Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months - Psychedelic Alpha
This morning, Compass Pathways announced that it is preparing to launch its psilocybin therapy (COMP360) for treatment-resistant depression (TRD) at least nine months earlier than previously planned…
psychedelicalpha.com
Pα+ Psychedelic Bulletin 212 - Delix Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II - NRx Wants FDA to Ban Its Competitors’ Ketamine - Cybin Trades Toxic Financing for Top Tier Investors in $175M Raise psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M - Psychedelic Alpha
Delix Therapeutics Posts Early Efficacy Signal for ‘Non-Hallucinogenic’ Neuroplastogen as FDA Clears At-Home Phase II • NRx Pharmaceuticals Wants FDA to Ban Its Competitors’ Ketamine •
psychedelicalpha.com
Q3’25 Psychedelic Lobbying Update Here, we share our analysis of the latest developments in federal psychedelics lobbying for our Pα+ subscribers. Here’s a review of Q3 2025 activity… psychedelicalpha.com/news/q325-ps...
Q3’25 Psychedelic Lobbying Update - Psychedelic Alpha
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. Here, we share our analysis of the latest developments for our Pα+ subscribers.
psychedelicalpha.com
Pα+ Psychedelic Bulletin #211: - AbbVie Officially Enters Psychedelics - atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation - California Bill Signed - No Commissioner's National Priority Voucher for Psychedelics - and more... psychedelicalpha.com/news/p%ce%b1...
Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; FDA Gives atai-Beckley’s 5-MeO-DMT Breakthrough Therapy Status; Newsom Signs Psychedelics Bill; No Priority Vouchers for Psychedel...
AbbVie Officially Enters Psychedelics as Gilgamesh Deal Closes, Patent Dispute Opens • BPL-003 Wins Breakthrough Status as atai Raises $150M • FDA Passes on Psychedelics in First Round of Priority Vou...
psychedelicalpha.com
A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda I speak with Schoevers, psychiatrist & epidemiologist who is, among other things, PI of PsyPal, a large, EU-funded study of psilocybin in patients w/ palliative care needs psychedelicalpha.com/news/a-europ...
A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda - Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman speaks with Robert Schoevers, Head of Psychiatry at University Medical Center Groningen and principal investigator of the EU-funded PsyPal study, about growing public ...
psychedelicalpha.com
Had a chat with @josh-hardman.bsky.social of @psychedelicalpha.bsky.social recently about recovered memories under #psychedelics. psychedelicalpha.com/news/recover...
Recovered or Reimagined? Samuli Kangaslampi on Psychedelics and Autobiographical Recall - Psychedelic Alpha
Psychedelic Alpha’s Josh Hardman speaks with clinical psychologist and trauma researcher Dr. Samuli Kangaslampi about how psychedelics affect autobiographical memory. They discuss the historical…
psychedelicalpha.com
Today, we launch The Psychedelic Practitioner by Psychedelic Alpha It’s designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. Read now: psychedelicalpha.com/news/the-psy...
The Psychedelic Practitioner: Issue 1 - Psychedelic Alpha
Welcome to the inaugural issue of The Psychedelic Practitioner, a new publication for the evolving practice of psychedelic care.
psychedelicalpha.com
Q3 2025 Psychedelic Investor Survey Results Today, we share topline results from the latest in our series of psychedelics investor surveys. Explore: psychedelicalpha.com/news/psyched...
The Psychedelic News Feed: Sept 29 - Oct 5, 2025 psychedelicalpha.com/news/the-psy...
The Psychedelic News Feed: Sept 29 - Oct 5, 2025 - Psychedelic Alpha
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing September 29, 2025.
psychedelicalpha.com
Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study We speak to researchers and take a deeper dive into the published study, with a focus on dose-response, safety, and MindMed's eschewing of psychotherapy. psychedelicalpha.com/news/breakth...
Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study - Psychedelic Alpha
MindMed’s Phase 2b LSD (MM120) for generalised anxiety disorder (GAD) study, published in JAMA earlier this month, shows promising efficacy and a favourable safety profile. Here…
psychedelicalpha.com